Session » Epidemiology and Health Services Research: Rheumatic Disease Pharmacoepidemiology
-
Abstract Number: 1812
A Retrospective Evaluation of the Clinical and Economic Implications of Gout in Nursing Home Residents in Hawaii Treated with Allopurinol
-
Abstract Number: 1813
Accuracy of Veterans Affairs Database for Gout-Related Health Care Utilization
-
Abstract Number: 1814
Comparing Clinical Characteristics and Comorbidities of Gout Patients Treated with Allopurinol or Febuxostat
-
Abstract Number: 1815
Factors Associated with a Prolonged Hospital Length of Stay for Patients with Acute Gout
-
Abstract Number: 1816
Relationship Between Race, Uric Acid Levels, Urate-Lowering Therapy and Resource Use in Patients with Gout
-
Abstract Number: 1817
The Role of Repeating Tuberculin Skin Tests During Biologic Therapy
-
Abstract Number: 1818
Latent Tuberculosis Detection and Tuberculosis Reactivation in Patients Receiving Anti-TNFá Drugs: A Nationwide Italian Survey
-
Abstract Number: 1819
Predictors of Pneumococcal Vaccination in Patients with Rheumatoid Arthritis and Systemic Lupus Erythematosus
-
Abstract Number: 1820
Human Papillomavirus Vaccine [Types 6, 11, 16, 18] (Gardasil®) and Autoimmune Disorders: Safety Assessment Using the Pharmacoepidemiologic General Research Extension System
-
Abstract Number: 1821
Clinical Predictors of Methotrexate-Induced Liver Enzyme Elevation in Patients with Rheumatoid Arthritis in an Electronic Medical Record
-
Abstract Number: 1822
Liver Toxicity Monitoring and Its Impact On Methotrexate Discontinuation in a National Cohort of Veterans
-
Abstract Number: 1823
Short Periods of Glucocorticoid Use Increase the Risk of Gastrointestinal Bleeding
-
Abstract Number: 1824
Do Statins Reduce the Incidence of Connective Tissue Disease? A Retrospective Cohort Study
-
Abstract Number: 1825
Work Disability and Work Limitations in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis Are Equal and Increase with Comorbidities
-
Abstract Number: 1827
Factors That Impact Work Productivity in the Preserve Trial: A Randomized Controlled Trial of Combination Etanercept-Methotrexate Therapy in Patients with Moderately Active Rheumatoid Arthritis
-
Abstract Number: 1828
Smoking Is Associated with Worse and More Widespread Pain, Worse Fatigue, General Health and Quality of Life in a Swedish Population Based Cohort of Patients with Psoriatic Arthritis
-
Abstract Number: 1829
Cost of Etanercept, Adalimumab, and Infliximab in Patients with Rheumatoid Arthritis with Employer Provided Health Insurance
-
Abstract Number: 1830
Drugs Are the Major Cost Driver of Rheumatoid Arthritis As Soon As the First Year of the Disease: An Economic Analysis Based On the Espoir Cohort Data
-
Abstract Number: 1831
Evaluation of the Cost-Effectiveness of Rheumatoid Arthritis Treatment with Biologic Agents Using the IORRA Cohort Database
-
Abstract Number: 1832
Evaluating the Cost-Effectiveness of Personalized Treatment with Adalimumab Using Serum Drug Levels in Rheumatoid Arthritis Patients
-
Abstract Number: 1833
Healthcare Costs in Psoriatic Arthritis Patients Newly Initiated On a Biologic Disease-Modifying Anti-Rheumatic Drug or Methotrexate
-
Abstract Number: 1834
Utilization and Expected Cost of Rheumatoid Arthritis Patients Treated with Golimumab: A Specialty Pharmacy Perspective
-
Abstract Number: 1836
Early Versus Delayed Initiation of Disease-Modifying Antirheumatic Drugs in Rheumatoid Arthritis
-
Abstract Number: 1837
Which Rheumatoid Arthritis, Ankylosing Spondylitis and Juvenile Idiopathic Arthritis Patients Initiate Anti-TNFá Therapy?
-
Abstract Number: 1838
10-Year Trends in the Use of Disease Modifying Anti-Rheumatic Drugs (DMARDs) and Biologic Agents in Rheumatoid Arthritis: A National Veteran Affairs Study
-
Abstract Number: 1839
The Progression of the Rate of Biologic Initiation in Early Rheumatoid Arthritis Is Constant Over the First 5 Years in the Espoir Cohort
-
Abstract Number: 1840
Treatment Patterns in Psoriatic Arthritis Patients Newly Initiated On Non-Biologic Disease-Modifying Anti-Rheumatic Drugs
-
Abstract Number: 1841
Lower Than Expected Levels of DMARD Acquisition Immediately Pre and Post Biologic Initiation in Rheumatoid Arthritis Patients
-
Abstract Number: 1842
Disease Activity and Treatment Strategies in Moderate Rheumatoid Arthritis Patient Population: Data From the Consortium of Rheumatology Researchers of North America
-
Abstract Number: 1843
Predictors of Starting and Stopping Disease Modifying Anti-Rheumatic Drugs for Rheumatoid Arthritis: A 23 Year Longitudinal Cohort
-
Abstract Number: 1844
Inequities in Access to Biologic Disease-Modifying Anti-Rheumatic Drugs for Patients with Rheumatoid Arthritis Across 46 European Countries
-
Abstract Number: 1845
Inequalities Across 46 European Countries in Clinical Eligibility Criteria for the Start of A First (Reimbursed) Biologic in Patients with Rheumatoid Arthritis
-
Abstract Number: 1846
Observation of Persistence Rates and Potential Costs Savings Associated with Certolizumab Pegol Treatment for Rheumatoid Arthritis in England, Wales and Northen Ireland Clinical Practice
-
Abstract Number: 1847
Status of the Rheumatology Clinical Trials Portfolio: Data From Clinicaltrials.Gov
-
Abstract Number: 1848
Impact of Biologics On Total Knee Replacement and Total Hip Replacement Rates in Rheumatoid Arthritis Patients: Results From US Marketscan Database
-
Abstract Number: 1850
Association of Clinical Trial Characteristics with Positive Study Outcome Reporting in Randomized Controlled Trials of Rheumatoid Arthritis Therapy
-
Abstract Number: 1851
Exploring the Relationship of Anti-Tumor Necrosis Factor Drugs and Methicillin Resistant Staphylococcus Aureus Nasal Colonization in Patients with Rheumatologic Conditions and Psoriasis
-
Abstract Number: 1852
Tumour Necrosis Factor-Alpha Antagonists and Alopecia: A Case/Non-Case Study in a Nationwide Pharmacovigilance Database
-
Abstract Number: 1853
Rheumatoid Arthritis Patients’ Experiences of Medication Side Effects and Subsequent Decision Making about Medications
-
Abstract Number: 1854
The Safety of Anti-TNF Biologic Agents in Rheumatoid Arthritis – A Meta-Analysis of 35 RCTs